Panitumumab Helps Colorectal Cancer Patients Get to Surgery
October 23, 2019
The VOLFI trial enrolled 105 patients with RAS wild-type metastatic colorectal cancer.
Christina Bennett, MS
Combo Therapy Shows Modest Survival Gain, More Toxicity for Gastric Cancer
October 22, 2019
A combination of trifluridine and tipiracil showed some gains in overall survival for patients with metastatic gastric cancer or gastroesophageal junction cancer.
Nivolumab and Bevacizumab Combo Shows Activity in Ovarian Cancer
October 18, 2019
Combination therapy with nivolumab and bevacizumab appeared to have clinical activity in ovarian cancer patients with platinum-sensitive or platinum-resistant disease.
Study Moves the Needle for Melanoma Patients with Rare BRAF Mutations
October 17, 2019
BRAF and MEK inhibitors appear to have clinical activity in patients with metastatic melanoma with rare BRAF mutations.
Untangling Breast Cancer Disparities in San Francisco
October 16, 2019
A new study looked at the characteristics of diagnosed breast cancer cases in San Francisco.
Lack of Patient Understanding of PFS Points to Bigger Issues
October 15, 2019
A study showed patients seem to lack an understanding of the meaning of progression-free survival.
Timing of Palliative Care Linked to Better Lung Cancer Survival
October 9, 2019
The study found patients with lung cancer referred to palliative care earlier lived longer.
High Recurrence Score Linked with Chemotherapy Success in Breast Cancer
October 8, 2019
The results of the TAILORx trial went against previous ideas that breast cancer patients with a high Oncotype score who needed chemotherapy and endocrine therapy wouldn't fare well.
Niraparib Shows “Impressive” Survival Improvements in Advanced Ovarian Cancer
October 2, 2019
Maintenance therapy with niraparib may improve survival in patients with ovarian cancer.
Olaparib Plus Bevacizumab Prolongs Survival in Advanced Ovarian Cancer
October 2, 2019
Adding PARP inhibitors to maintenance therapy was shown to prolong progression-free survival in patients with advanced ovarian cancer.
